Vaginal practices, microbicides and HIV: what do we need to know?
- 1Institute of Social and Preventive Medicine, University of Bern, Switzerland
- 2International Centre for Reproductive Health, Kenya
- 3Academic Medical Center, Center for Poverty-Related Communicable Diseases, Amsterdam, The Netherlands
- 4Reproductive Health and HIV Research Unit, University of Witwatersrand, South Africa
- 5Department of Obstetrics and Gynaecology, Ghent University, Belgium
- Correspondence to: MsA Martin Hilber Institute of Social and Preventive Medicine, University of Bern, Finkenhubelweg 11, CH-3012 Bern, Switzerland;
- Accepted 2 October 2007
The goal of a safer vaginal environment could be reached by identifying harmful vaginal practices and an effective microbicide, thereby increasing options for HIV prevention
The global burden of HIV, its increasing feminisation, and chronic difficulties with development of options for HIV prevention all argue for an intensified re-examination of factors influencing the efficiency of heterosexual HIV transmission. This includes vaginal practices and products used by large numbers of women worldwide to tighten, dry, warm and clean their vagina. Women’s efforts to change their genital environment can undermine each component of innate defences against pathogens.1 In particular, vaginal practices have been linked with loss of lactobacilli and disruption of the vaginal epithelium.2–4 These practices may therefore be an important mediator in acquisition of STI, including HIV, or worsen pre-existing infections. Despite this, surprisingly little is known about the effects of specific vaginal practices on HIV transmission dynamics.
In past decades, both cross-sectional and longitudinal studies have found an association between intravaginal cleansing and adverse reproductive outcomes, including pelvic inflammatory disease, ectopic pregnancy and bacterial vaginosis (BV).1,5,6 BV could be an intermediary factor between vaginal practices and HIV infection (fig 1). Though much uncertainty remains about the pathophysiology of BV, its accompanying inflammatory milieu, characterised by pro-inflammatory cytokines and immune cell changes, is likely to enhance HIV transmission.7 Also, immunological changes with BV can stimulate HIV expression, raising HIV levels in the genital tract virus and likely the infectivity of women.7 Acquisition of HSV-2 may also be higher among women with BV.8